|Articles|May 1, 2019
- Pharmaceutical Executive-05-01-2019
- Volume 39
- Issue 5
Pharmaceutical Executive, May 2019 Issue (PDF)
Click the title above to open the Pharmaceutical Executive May 2019 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 6 years ago
Impact Investing and R&Dover 6 years ago
New Flare-Up in Europe's External Reference Pricing Debateover 6 years ago
It’s Time for a Chief Adherence Officerover 6 years ago
Adopting New Technology: Barriers and Breakthroughsover 6 years ago
The CFO Evolutionover 6 years ago
We’ve Got You Coveredover 6 years ago
Survey Spotlights the CFO’s Strategic Riseover 6 years ago
FDA After Gottlieb: Thorny Issues, Political Challengesover 6 years ago
Easing the Path to Profitabilityover 6 years ago
A Strategic Approach to Pharma R&D Portfolio PlanningNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Lilly’s Orforglipron, Retatrutide Named as Defining GLP-1 Drugs of the Next Decade
2
Eli Lilly Enters $1.2 Billion Definitive Agreement to Acquire Ventyx Biosciences
3
FDA Limits Regulations on Non-Medical Grade Wearable Fitness Devices
4
GSK Enters Multi-Year Collaboration with Helix to Develop Precision Medications
5